We use cookies to analyze site traffic and improve your experience.
By accepting, you consent to the use of analytics cookies.

FHB:NASDAQFirst Hawaiian, Inc. Analysis

Data as of 2026-09-26 - not real-time

$25.25

Latest Price

3/10Risk

Risk Level: Low

Executive Summary

First Hawaiian, Inc. is priced at $25.25, and its moving averages give no clean directional read — the structure is neutral. The last 30 days have lost 9.4%. Relative strength is 38.5 — approaching oversold — and the MACD signal is bullish. Watch $24.67 as support and $26.18 as the nearer resistance level.
The shares look undervalued, trading on 11.0 times earnings below a sector average of 15.6. Sell-side targets cluster 20.6% above the current quote. Revenue is growing at 5.9% on a 32.3% profit margin. The 4.12% dividend yield looks covered by current payout levels.
Risk scores 3 out of 10, which is low for this asset class. With 30-day volatility of 14.5%, a beta of 0.68 and a maximum drawdown of 18.3%, the drawdown profile is forgiving relative to most of the market. The wider market backdrop reads extreme greed at 95 on the fear-greed composite.
The horizons diverge: hold near-term but buy on a long view, at 6/10 conviction over the longer horizon.

Top Market Events

The end of the earnings season is always a good time to take a step back and see who shined and who didn’t .Detailed price information for First Hawaiian Inc FHB-Q from The Globe and Mail including charting and trades.Detailed price information for First Hawaiian Inc FHB-Q from The Globe and Mail including charting and trades.

Market Outlook

Short Term

< 1 year
Neutral
Model confidence: 4/10

Key Factors

  • Trading below the 200-day average of 26.69
  • MACD momentum is positive
  • 30-day price change of -9.4%

Medium Term

1–3 years
Positive
Model confidence: 5/10

Key Factors

  • P/E of 11.0 versus sector average of 15.6
  • Trading below the 200-day average of 26.69
  • Analyst targets imply +20.6% versus the current price

Long Term

> 3 years
Positive
Model confidence: 6/10

Key Factors

  • P/E of 11.0 versus sector average of 15.6
  • Analyst targets imply +20.6% versus the current price
  • Profit margin of 32.3% is healthy

Key Metrics & Analysis

Financial Health

Revenue Growth5.90%
Profit Margin32.34%
P/E Ratio11.0
ROE10.32%
ROA1.20%
P/B Ratio1.1
Op. Cash Flow$334.9M
Industry P/E15.6

Technical Analysis

TrendNeutral
RSI38.5
Support$24.67
Resistance$26.18
MA 20$25.60
MA 50$26.79
MA 200$26.69
MACDBullish
VolumeIncreasing
Fear & Greed Index94.88

Valuation

Fair Value$38.03
Target Price$30.44
Upside/Downside20.57%
GradeUndervalued
TypeValue
Dividend Yield4.12%

Risk Assessment

Beta0.68
Volatility14.46%
Sector RiskMedium
Reg. RiskHigh
Geo RiskLow
Currency RiskLow
Liquidity RiskLow

This analysis may contain inaccuracies and is provided for informational and research purposes only. It is not personal investment advice, a recommendation, or an instruction to buy, sell, or hold any asset.